Capstone Therapeutics (CAPS) Announces Initiation Of Dosing For AEM-28 Phase 1b/2a Human Clinical Trial In Refractory Hypercholesterolemic Subjects
6/12/2014 7:23:53 AM
TEMPE, Ariz., June 11, 2014 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, LLC ("JV"), announced today the initiation of dosing for the AEM-28 (Apo E mimetic peptide) Phase 1b/2a human clinical trial in refractory hypercholesterolemic subjects who are already on optimal cholesterol lowering therapy but are unable to reach target cholesterol levels.
Help employers find you! Check out all the jobs and post your resume.
comments powered by